This document is a publication of a European patent application (EP4247853A1) by Bliss Biopharmaceutical (Hangzhou) Co., Ltd., detailing a modified EGFR antibody drug conjugate. The application covers the antibody itself, the conjugate formed with a drug, and its therapeutic applications, particularly in oncology. The publication date is March 11, 2026.

As this is a patent application publication, it does not impose immediate compliance obligations on regulated entities. However, it signifies potential future intellectual property rights and market exclusivity for the applicant in the designated European states. Companies operating in the pharmaceutical and biotechnology sectors, especially those involved in antibody-drug conjugate development or EGFR-targeted therapies, should monitor the progress of this patent application through its examination and potential grant stages.